p300 and its close paralog CBP are well characterized lysine acetyltransferases (KAT; refs. 27, 28), and p300 has been shown to promote melanoma progression through multiple mechanisms, including regulation of MITF function (26, 29), direct acetylation of BRAF to enhance its kinase activity (30), an emerging role in therapy resistance (31), and as a potential driver of acral melanoma through genetic amplification of the EP300 locus (32). This evidence concerns the gene BRAF and melanoma.